These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8328104)

  • 21. [Management of refractory and fulminating colitis].
    Turunen U
    Duodecim; 1987; 103(14):890-6. PubMed ID: 3328677
    [No Abstract]   [Full Text] [Related]  

  • 22. The mesalamine wars heat up-enter balsalazide.
    Cohen RD
    Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
    [No Abstract]   [Full Text] [Related]  

  • 23. [Mesalazine is effective in Crohn disease].
    Quartarolo JP
    Ugeskr Laeger; 2005 Apr; 167(16):1767. PubMed ID: 15898611
    [No Abstract]   [Full Text] [Related]  

  • 24. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine?
    Colombel JF; Brabant G; Gubler MC; Locquet A; Comes MC; Dehennault M; Delcroix M
    Lancet; 1994 Aug; 344(8922):620-1. PubMed ID: 7914992
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mesalazine is effective in Crohn disease 1].
    Fallingborg J; Langholz E; Christensen LA; Munkholm P; Dahlerup JF
    Ugeskr Laeger; 2005 Mar; 167(11):1307-8; author reply 1309. PubMed ID: 15830509
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mesalazine is effective in Crohn disease 2].
    Quartarolo JP; Laegemidler F; Eskerod O
    Ugeskr Laeger; 2005 Mar; 167(11):1308-9; author reply 1309. PubMed ID: 15830510
    [No Abstract]   [Full Text] [Related]  

  • 27. [Mesalazine is without clinical effect in patients with Crohn disease].
    Munck LK
    Ugeskr Laeger; 2005 Jan; 167(3):302-3. PubMed ID: 15704804
    [No Abstract]   [Full Text] [Related]  

  • 28. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A study of 5-ASA use among young patients with Crohn disease. Regular drug revision is of significance for all children with chronic disease].
    Hedin A; Ehrsson H; Eksborg S; Finkel Y; Hildebrand H; Lidehäll AK
    Lakartidningen; 2001 Oct; 98(40):4343-6. PubMed ID: 11685756
    [No Abstract]   [Full Text] [Related]  

  • 30. Medical treatment of inflammatory bowel disease.
    Singhal A; Kar P
    J Assoc Physicians India; 1995 Sep; 43(9):627-31. PubMed ID: 8773067
    [No Abstract]   [Full Text] [Related]  

  • 31. [Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review].
    Thomsen OØ; Nielsen OH
    Ugeskr Laeger; 2005 Aug; 167(33):3015-7. PubMed ID: 16109240
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral balsalazide (Colazal) for ulcerative colitis.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):62-3. PubMed ID: 11468602
    [No Abstract]   [Full Text] [Related]  

  • 35. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease.
    Calviño J; Romero R; Pintos E; Losada E; Novoa D; Güimil D; Mardaras J; Sanchez-Guisande D
    Clin Nephrol; 1998 Apr; 49(4):265-7. PubMed ID: 9582560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 37. [Angioedema in Crohn's disease possibly due to mesalazine].
    Nguyen-Khac E; Le Baron F; Thevenot T; Tiry-Lescut C; Tiry F
    Gastroenterol Clin Biol; 2002 May; 26(5):535-6. PubMed ID: 12122371
    [No Abstract]   [Full Text] [Related]  

  • 38. Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Rasmussen SN
    J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis.
    Rymes N; Glick L; Holmes JA
    Bone Marrow Transplant; 1996 Aug; 18(2):484. PubMed ID: 8864473
    [No Abstract]   [Full Text] [Related]  

  • 40. [New therapeutic data in inflammatory colitis].
    Karsenti P
    Ann Gastroenterol Hepatol (Paris); 1996; 32(1):10. PubMed ID: 8669802
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.